DE69633127D1 - Verwendung von heparinasen zur verminderung von entzündungsreaktionen - Google Patents

Verwendung von heparinasen zur verminderung von entzündungsreaktionen

Info

Publication number
DE69633127D1
DE69633127D1 DE69633127T DE69633127T DE69633127D1 DE 69633127 D1 DE69633127 D1 DE 69633127D1 DE 69633127 T DE69633127 T DE 69633127T DE 69633127 T DE69633127 T DE 69633127T DE 69633127 D1 DE69633127 D1 DE 69633127D1
Authority
DE
Germany
Prior art keywords
heparinase
endothelium
localized
heparin
activated endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633127T
Other languages
English (en)
Other versions
DE69633127T2 (de
Inventor
Clark Bennett
Elizabeth Cauchon
Dominique Fink
Brigette Grouix
Ariane Hsia
Pamela Danagher
Joseph Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of DE69633127D1 publication Critical patent/DE69633127D1/de
Application granted granted Critical
Publication of DE69633127T2 publication Critical patent/DE69633127T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69633127T 1995-09-29 1996-09-27 Verwendung von heparinasen zur verminderung von entzündungsreaktionen Expired - Fee Related DE69633127T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US462295P 1995-09-29 1995-09-29
US604622 1995-09-29
PCT/US1996/015593 WO1997011684A1 (en) 1995-09-29 1996-09-27 Use of heparinases to decrease inflammatory responses
US08/722,659 US20010006635A1 (en) 1995-09-29 1996-09-27 Use of heparinase to decrease inflammatory responses

Publications (2)

Publication Number Publication Date
DE69633127D1 true DE69633127D1 (de) 2004-09-16
DE69633127T2 DE69633127T2 (de) 2005-08-04

Family

ID=26673252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633127T Expired - Fee Related DE69633127T2 (de) 1995-09-29 1996-09-27 Verwendung von heparinasen zur verminderung von entzündungsreaktionen

Country Status (11)

Country Link
US (3) US20010006635A1 (de)
EP (2) EP0852491B1 (de)
JP (1) JP3713276B2 (de)
AT (1) ATE273020T1 (de)
AU (1) AU703394B2 (de)
CA (1) CA2233343A1 (de)
DE (1) DE69633127T2 (de)
DK (1) DK0852491T3 (de)
ES (1) ES2227611T3 (de)
PT (1) PT852491E (de)
WO (1) WO1997011684A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
CA2242693C (en) * 1997-09-04 2002-09-17 Becton, Dickinson And Company Additive formulation and method of use thereof
WO1999043830A2 (en) 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1026250A1 (de) * 1998-12-02 2000-08-09 Aventis Behring GmbH DNs-Konstructs von Blutgerinnungsfaktoren und P-Selektin
EP1010762A1 (de) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNS-Konstrukte von Blutgerinnungsfaktoren und P-Selektin
ES2269211T3 (es) 1999-12-22 2007-04-01 Ucb, S.A. Enzimas homologas de la heparanasa humana y sus variantes de empalme.
WO2001066772A2 (en) 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
EP1974752B1 (de) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subzelluläres Targeting von therapeutischen Proteinen
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
JP4773976B2 (ja) * 2004-01-30 2011-09-14 エモリー ユニバーシティ 神経再生を促進する材料および方法
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
CN1312183C (zh) * 2004-05-19 2007-04-25 清华大学 一种肝素酶i融合蛋白及其编码基因与表达方法
CN100344769C (zh) * 2005-08-04 2007-10-24 清华大学 一种制备低分子量肝素的方法
US7767420B2 (en) * 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7691613B2 (en) * 2006-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Glycosaminoglycan lyase IV and uses thereof
US7691612B2 (en) * 2005-11-03 2010-04-06 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
EP2279210B1 (de) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und ihre verwendung
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
BR112015020477B1 (pt) * 2013-02-28 2019-10-29 Kao Corp processo, uso e kit para alisamento semipermanente dos cabelos
JP7330893B2 (ja) 2017-03-10 2023-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
WO2019090203A1 (en) 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
JP7538724B2 (ja) 2018-06-20 2024-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 細胞保護の方法と組成物
JP2023501568A (ja) * 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941664A (en) * 1959-02-19 1963-11-13 Henry Thompson Stanton Jr Buccal or sublingual tablet containing carbohydra e enzyme for controlling inflammation
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
US5169772A (en) * 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
WO1991002977A1 (en) * 1989-08-23 1991-03-07 Hadassah Medical Organization Wound healing preparations containing heparanase
US5099855A (en) 1989-11-09 1992-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Methods of and apparatus for monitoring respiration and conductive gel used therewith
CA2090427A1 (en) * 1990-08-27 1992-02-28 Cetus Oncology Corporation Cd18 peptide medicaments for the treatment of disease
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
US5714376A (en) * 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
DK75593D0 (de) 1993-06-25 1993-06-25 Novo Nordisk As
CA2176934A1 (en) * 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes

Also Published As

Publication number Publication date
DK0852491T3 (da) 2004-12-20
ATE273020T1 (de) 2004-08-15
EP0852491B1 (de) 2004-08-11
CA2233343A1 (en) 1997-04-03
WO1997011684A1 (en) 1997-04-03
US20060140928A1 (en) 2006-06-29
EP0852491A1 (de) 1998-07-15
AU703394B2 (en) 1999-03-25
JPH11512721A (ja) 1999-11-02
EP1552846A3 (de) 2008-05-07
AU7379196A (en) 1997-04-17
US7264799B2 (en) 2007-09-04
DE69633127T2 (de) 2005-08-04
EP0852491A4 (de) 2002-08-07
US20010006635A1 (en) 2001-07-05
ES2227611T3 (es) 2005-04-01
EP1552846A2 (de) 2005-07-13
US20050191288A1 (en) 2005-09-01
JP3713276B2 (ja) 2005-11-09
PT852491E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
ATE273020T1 (de) Verwendung von heparinasen zur verminderung von entzündungsreaktionen
Bar-Shavit et al. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties.
US5872109A (en) Anti-inflammatory agent
DE69426879D1 (de) Plasma-artige lösung
CURTISS JR Changes produced in the synovial membrane and synovial fluid by disease
ATE344051T1 (de) Verwendung von bakteriellen enzymen z.b. heparinasen, chodroitinasen um wundheilungprozesse zu modulieren
CA2212537A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
ATE113636T1 (de) Zusammensetzung und methode zur verhütung von verklebungen zwischen körpergewebe.
BR9708468A (pt) Tratamento de fotoferese de leucocitos.
DE3856321D1 (de) Sulfatierte Polysaccharide mit antiinflammatorischer Aktivität
ATE275932T1 (de) Verwendung bestimmter polyalkoxy compolymere für die behandlung von schuppen
DE69637825D1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
BINO et al. The kidney is the main site of interferon degradation
EP0372670A3 (de) Hirudinverwandte Peptide zur Verhinderung der Plättchenaggregation
DE68912020D1 (de) N-2,3-Butadienyl-tri-aminoalkanderivate.
TR200501763T1 (tr) T
WO2001019376A3 (en) METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
Aoike et al. Ulinastatin gives rise to an effectual diuresis in oliguric acute renal failure
CA1315676C (en) Heparin neutralization using compounds immobilized and in direct contact with whole blood
Silver IBT 9302 (Heparinase III): a novel enzyme for the management of reperfusion injury-related vascular damage, restenosis and wound healing
Leonsins Dextran: a valuable plasma volume expander
Esmon Platelets are anticoagulants?
Ashok et al. Comparative study of conventional dressing vs. topical heparin dressing in lower limb diabetic ulcers
Bartlett et al. Venular and Arterial Endothelial Cells Differ in their Expression of Adhesion Molecules and in their Ability to Degrade the Subendothelial Basement Membrane
Daudi Fibronectin fragments: Relationship to lung vascular injury during intravascular coagulation.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOCKHORNI & KOLLEGEN, 80687 MUENCHEN

8339 Ceased/non-payment of the annual fee